Clinical Trial Update: Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the safety and immunogenicity of a recombinant WT1 antigen-specific cancer immunotherapy combined with infusion of regulator…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Recombinant WT1 antigen-specific cancer immunotherapeutic
• Treg-depleted T cell infusion

Snippet

Sponsor: Jules Bordet Institute | Conditions: Acute Myelogenous Leukemia, Myeloid Leukemia in Remission | Phase 1, Phase 2 | Status: UNKNOWN